抗体药物偶联物相关呼吸系统疾病:法国与WHO药物警戒数据库联合分析
本研究结合法国药物警戒数据库的专家审评与VigiBase®的不比例分析,描述抗体药物偶联物相关呼吸系统不良反应并识别安全信号。71例描述性分析中83.1%发生间质性肺病,主要见于德曲妥珠单抗;不比例分析显示多种抗体药物偶联物与间质性肺病、肺动脉高压及胸膜疾病存在显著信号。
要点
- 抗体药物偶联物相关间质性肺病中位发生时间为4个月,肺动脉高压为45个月。
- 不比例分析显示间质性肺病信号见于维布妥昔单抗、泊洛妥珠单抗、恩美曲妥珠单抗和德曲妥珠单抗。
- 仅恩美曲妥珠单抗显示肺动脉高压显著信号,除贝兰他单抗莫福汀和恩诺单抗维多汀外均与胸膜疾病信号相关。
核心结论
- 真实世界中抗体药物偶联物相关间质性肺病风险突出,肺动脉高压和胸膜疾病为额外安全信号。
研究设计与样本
- 对法国药物警戒数据库中抗体药物偶联物相关呼吸系统不良反应进行描述性分析并专家审评,纳入71例患者。
- 使用VigiBase®对间质性肺病、肺动脉高压和胸膜疾病进行不比例分析。
主要发现
- 71例中女性56例(78.9%),中位年龄60岁,71.8%为乳腺癌患者。
- 9例(12.7%)发生肺动脉高压,3例(4.2%)发生胸膜疾病,主要见于恩美曲妥珠单抗。
- 中位发生时间:胸膜疾病1个月,间质性肺病4个月,肺动脉高压45个月。
- 不比例分析显示间质性肺病显著信号见于维布妥昔单抗、泊洛妥珠单抗、恩美曲妥珠单抗和德曲妥珠单抗。
关键数值与推荐
- 间质性肺病显著信号:维布妥昔单抗、泊洛妥珠单抗、恩美曲妥珠单抗、德曲妥珠单抗。
- 肺动脉高压显著信号:仅恩美曲妥珠单抗。
- 胸膜疾病显著信号:除贝兰他单抗莫福汀和恩诺单抗维多汀外的所有抗体药物偶联物。
临床怎么用
- 临床使用抗体药物偶联物时应监测呼吸系统症状,尤其关注间质性肺病、肺动脉高压和胸膜疾病。
局限性
- 需基于人群的研究进一步确认发现并识别抗体药物偶联物及患者相关危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates are proving to be highly effective in oncology, yet their real-world respiratory safety profile remains largely unknown. This study sought to characterize drug-linked respiratory disorders and identify safety signals. We performed a descriptive analysis with expert review of respiratory adverse drug reactions related to antibody-drug conjugates from the French pharmacovigilance database. We also conducted disproportionality analyses for interstitial lung disease, pulmonary arterial hypertension, and pleural disorder using VigiBase®. Among the 71 patients included in the descriptive study, 56 (78.9%) were women, and the median age was 60 years. Most (71.8%) were treated for breast cancer. Fifty-nine patients (83.1%) developed antibody-drug conjugate-related interstitial lung disease, primarily after trastuzumab deruxtecan. Nine patients (12.7%) developed pulmonary arterial hypertension and three (4.2%) contracted pleural disorders, mainly after trastuzumab emtansine. The median time to onset varied by clinical feature, with 1 month for pleural disorder, 4 months for interstitial lung disease, and 45 months for pulmonary arterial hypertension. The disproportionality analysis showed a significant signal for interstitial lung disease with brentuximab vedotin, polatuzumab vedotin, trastuzumab emtansine, and trastuzumab deruxtecan. Only trastuzumab emtansine had a significant signal for pulmonary arterial hypertension. All antibody-drug conjugates, except belantamab mafodotin and enfortumab vedotin, were associated with a significant signal for pleural disorders. Our study highlights the risk of interstitial lung disease with these drugs in real-world settings and identified pulmonary arterial hypertension and pleural disorders as additional safety signals. Further research is needed to confirm these findings in population-based studies and to identify antibody-drug conjugates and patient-related risk factors.
引用
- Mirleau V, Hlavaty A, Jutant EM, et al. Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases. Clin Pharmacol Ther. 2025. PMID: 41199633. doi:10.1002/cpt.70119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。